-
公开(公告)号：US20250064949A1
公开(公告)日：2025-02-27
申请号：US18946447
申请日：2024-11-13
Inventor： Brock A. LINDSEY , Justin E. MARKEL , Ryan A. LACINSKI , Jabeen NOORE
IPC: A61K47/62 , A61K9/51 , A61K31/43 , A61K31/7036 , A61K38/20
Abstract: The present disclosure provides compositions comprising protein encapsulated nanoparticles, and methods of making said compositions. In an aspect, a composition may comprise a drug delivery vector and a therapeutic substance, wherein the composition elutes at least 1.0 pg of the therapeutic substance per 100,000 particles of the drug delivery vector over a period of time under conditions of a drug delivery vector release buffer, wherein the therapeutic substance, drug delivery vector and drug delivery vector release buffer comprise a solution, wherein the solution is centrifuged and a portion stored at about 1 to 10° C., and wherein the elution of the therapeutic substance is determined by ELISA assay. This disclosure further describes a method of controlling an immunophenotype in a patient suffering from a disease which impacts the immune system.
-
公开(公告)号：US12233103B2
公开(公告)日：2025-02-25
申请号：US18298263
申请日：2023-04-10
Applicant: IO BIOTECH APS
Inventor： Mads Hald Andersen , Per Thor Straten
Abstract: The invention relates to the field of prophylaxis and therapy of cancer. Provided is a Indoleamine 2,3-dioxygenase (IDO) or peptide fragments hereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived herefrom or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. The invention also provides that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. The invention further provides the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.
-
公开(公告)号：US20250059564A1
公开(公告)日：2025-02-20
申请号：US18785522
申请日：2024-07-26
Applicant: KRIYA THERAPEUTICS, INC.
Inventor： Brian FURMANSKI , Nachiketa GUPTA , Bruce SCHNEPP , Michele STONE
IPC: C12N15/86 , A61K38/20 , A61K39/395 , A61P35/00
Abstract: The present disclosure provides the gene therapy compositions comprising vectors (e.g., viral vectors) suitable for delivery of nucleic acids encoding immunomodulatory proteins or functional fragments thereof, and methods of using the same. Certain aspects of the disclosure are directed to an adeno-viral vector (AAV) delivery of nucleic acids encoding two or more immunomodulatory proteins or functional fragments thereof to a tumor.
-
公开(公告)号：US20250057765A1
公开(公告)日：2025-02-20
申请号：US18782767
申请日：2024-07-24
Applicant: Translate Bio, Inc.
Inventor： Christian Cobaugh , Richard Wooster , Frank DeRosa , Anusha Dias , Shrirang Karve
Abstract: The present invention provides, among other things, methods and compositions for cancer treatment. The methods and compositions disclosed herein are particularly effective in reducing the size/volume of a tumor and inhibiting tumor growth.
-
公开(公告)号：US20250057760A1
公开(公告)日：2025-02-20
申请号：US18934892
申请日：2024-11-01
Applicant: Neurotech USA, Inc.
Inventor： Jeffrey Louis GOLDBERG , Cahil Mcgovern , Weng Tao , Konrad A. Kauper
Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.
-
公开(公告)号：US20250041386A1
公开(公告)日：2025-02-06
申请号：US17596538
申请日：2020-06-18
Applicant: Janssen Sciences Ireland Unlimited Company
Inventor： Helen Horton , Dorien De Pooter , Daniel Boden
Abstract: IL12 fusion proteins containing an IL12 p40 subunit, a linker and an IL12 p35 subunit are described. Also described are nucleic acids encoding the fusion proteins, vectors comprising the nucleic acids, and methods of using the fusion proteins and the nucleic acids encoding the fusion proteins to enhance immune responses to antigens.
-
公开(公告)号：US12215131B2
公开(公告)日：2025-02-04
申请号：US18314205
申请日：2023-05-09
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Jiaxi Wu , Tong Zhang , Maria del Pilar Molina-Portela , Eric Smith , Chia-Yang Lin , Thomas Craig Meagher
IPC: C07K14/55 , A61K35/17 , A61K38/00 , A61K38/20 , A61K39/00 , A61K47/68 , A61P35/00 , C07K14/705 , C07K14/715 , C07K14/725 , C07K14/74
Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
-
公开(公告)号：US20250032609A1
公开(公告)日：2025-01-30
申请号：US18777075
申请日：2024-07-18
Applicant: Vaccinex, Inc.
Inventor： Elizabeth E. Evans , Ernest S. Smith , Maurice Zauderer
IPC: A61K39/395 , A61K31/675 , A61K35/15 , A61K38/20 , A61K39/00 , A61P35/00 , A61P37/04 , C07K14/47 , C07K14/705 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12N5/0783 , G01N33/50
Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
-
公开(公告)号：US20250025559A1
公开(公告)日：2025-01-23
申请号：US18914453
申请日：2024-10-14
Applicant: THE METHODIST HOSPITAL
Inventor： Wenhao CHEN , Xian Chang LI
IPC: A61K45/06 , A61K35/17 , A61K38/20 , A61K39/00 , A61K39/395 , A61P35/00 , C07K14/47 , C07K16/28 , C12N5/0783 , C12N15/86
Abstract: Methods to treat cancer in a subject comprising administering to the subject a therapeutically effective amount of T-cells of the subject having increased IRF4 polypeptide expression compared to a control are disclosed. Also disclosed are methods of increasing tumor reactivity of a T-cell by increasing IRF4 polypeptide expression, and methods to predict the likelihood that a subject having cancer will respond therapeutically to administered T-cells having increased IRF4 polypeptide expression. Also disclosed are compositions comprising a T-cell and a viral vector encoding an IRF4 polypeptide. The compositions are methods are useful for treating numerous cancers in which higher level expression of IRF4 in T-cells would be beneficial. In some embodiments, activated tumor-specific T-cells having increased IRF4 expression have greater infiltration in tumors and enhanced local immunological responses.
-
公开(公告)号：US12202872B2
公开(公告)日：2025-01-21
申请号：US17663384
申请日：2022-05-13
Applicant: Bristol-Myers Squibb Company
Inventor： Mary Struthers , Jonathan Harry Davis , Michael Louis Doyle , Priyanka Apurva Madia
IPC: C07K14/55 , A61K38/17 , A61K38/20 , A61K47/65 , A61P37/04 , C07K14/715 , C07K16/28 , C12N15/62 , A61K38/00
Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
